Company Overview
Company Type: Private Company
Website: dalcorpharma.com
Number of Employees: -
Year Founded: 2015
Total Amount Raised (CAD mm)†: 260.56
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
DalCor Pharmaceuticals Canada Inc. operates as a biopharmaceutical company. The company focuses on pharmacogenomic precision medicine for cardiovascular diseases. The company was incorporated in 2015 and is headquartered in Montreal, Canada with additional offices in Sarasota, Florida; Switzerland; and the United Kingdom.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Laghrissi-Thode, Fouzia 
CEO & Director

Key Board Members
Name
Title
Laghrissi-Thode, Fouzia 
CEO & Director
Etroy, Stéphane
Director


Primary Industry Classification
Biotechnology


Primary Office Location
2001 Boulevard Robert Bourassa Suite 1700 | Montreal, QC | H3A 2A6 | Canada
Phone: 514-508-5099   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Fonds de Developpement Économique
Sep-13-2023
Minority
-
Series D
Caisse de dépôt et placement du Québec
Apr-01-2016
Minority
-
Series B
CTI Life Sciences
Apr-01-2016
Unknown
-
Series B
Fonds de solidarité FTQ
Apr-01-2016
Unknown
-
Series B
Sanderling Ventures
Apr-01-2016
Unknown
-
Series B


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-13-2023
Sep-13-2023
Private Placement
Target
DalCor Pharmaceuticals Canada Inc.
Fonds de solidarité FTQ,CTI Life Sciences,Fonds de Developpement Économique

80.00
Apr-01-2016
Apr-01-2016
Private Placement
Target
DalCor Pharmaceuticals Canada Inc.
Sanderling Ventures,Caisse de dépôt et placement du Québec,Fonds de solidarité FTQ,CTI Life Sciences

76.51
Dec-31-2015
Dec-31-2015
Private Placement
Target
DalCor Pharmaceuticals Canada Inc.


36.04
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-13-2023
Product-Related Announcements
DalCor Pharmaceuticals Announces Dal-GenE-2 Confirmatory Trial
Sep-13-2023
Private Placements
DalCor Pharmaceuticals Canada Inc. announced that it has received $80 million in funding from Fonds de solidarité FTQ, CTI Life Sciences, Fonds de Developpement Économique
Jan-11-2021
Product-Related Announcements
Dalcor Pharmaceuticals Announces the Initiation of Dal-Covid, a Phase 2 Proof-Of-Concept Study for Dalcetrapib as a Potential Oral Anti-Viral Treatment for Covid-19
Jul-27-2020
Product-Related Announcements
Dalcor Announces Dal-Gene Trial Continues with Final Data Expected in the First Half of 2021
Jan-27-2020
Product-Related Announcements
DalCor Pharmaceuticals Announces Dal-Gene Trial to Continue as Planned Following Interim Futility Analysis


Advisors
Private Placement Advisors
Aquilo Partners, L.P., Jones Day, Osler, Hoskin & Harcourt LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 02:35 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc
Reports
39
GlobalData

Jun 16, 2023 01:00 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc
Reports
38
GlobalData

Mar 15, 2023 12:22 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc
Reports
38
GlobalData

Dec 14, 2022 11:13 PM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc
Reports
43
GlobalData

Dec 13, 2022 03:11 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Sep 21, 2022 05:07 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc
Reports
43
GlobalData

Aug 29, 2022 03:34 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Jun 16, 2022 05:10 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25
GlobalData

Jun 14, 2022 12:42 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc
Reports
43
GlobalData

Mar 16, 2022 10:04 AM
DalCor Pharmaceuticals Canada Inc.
DalCor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Dalcetrapib (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Laghrissi-Thode, Fouzia 
CEO & Director
514-508-5099
-

Etroy, Stéphane
Director
514-508-5099
-
setroy@cdpq.com
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Laghrissi-Thode, Fouzia 
CEO & Director
514-508-5099
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
